CA2859498A1 - Advertisement providing apparatus and method for providing advertisements - Google Patents

Advertisement providing apparatus and method for providing advertisements Download PDF

Info

Publication number
CA2859498A1
CA2859498A1 CA2859498A CA2859498A CA2859498A1 CA 2859498 A1 CA2859498 A1 CA 2859498A1 CA 2859498 A CA2859498 A CA 2859498A CA 2859498 A CA2859498 A CA 2859498A CA 2859498 A1 CA2859498 A1 CA 2859498A1
Authority
CA
Canada
Prior art keywords
seq
chain variable
variable region
advertising
providing apparatus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2859498A
Other languages
French (fr)
Inventor
Chae-Young Lim
Dong-Ouk Park
Jeong-Eun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Electronics Co Ltd
Original Assignee
Samsung Electronics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Electronics Co Ltd filed Critical Samsung Electronics Co Ltd
Priority claimed from PCT/KR2012/010918 external-priority patent/WO2013089487A1/en
Publication of CA2859498A1 publication Critical patent/CA2859498A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W88/00—Devices specially adapted for wireless communication networks, e.g. terminals, base stations or access point devices
    • H04W88/02—Terminal devices
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/16—Constructional details or arrangements
    • G06F1/1613—Constructional details or arrangements for portable computers
    • G06F1/1633—Constructional details or arrangements of portable computers not specific to the type of enclosures covered by groups G06F1/1615 - G06F1/1626
    • G06F1/1684—Constructional details or arrangements related to integrated I/O peripherals not covered by groups G06F1/1635 - G06F1/1675
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/16—Constructional details or arrangements
    • G06F1/1613—Constructional details or arrangements for portable computers
    • G06F1/1633—Constructional details or arrangements of portable computers not specific to the type of enclosures covered by groups G06F1/1615 - G06F1/1626
    • G06F1/1684—Constructional details or arrangements related to integrated I/O peripherals not covered by groups G06F1/1635 - G06F1/1675
    • G06F1/1694—Constructional details or arrangements related to integrated I/O peripherals not covered by groups G06F1/1635 - G06F1/1675 the I/O peripheral being a single or a set of motion sensors for pointer control or gesture input obtained by sensing movements of the portable computer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F15/00—Digital computers in general; Data processing equipment in general
    • G06F15/16—Combinations of two or more digital computers each having at least an arithmetic unit, a program unit and a register, e.g. for a simultaneous processing of several programs
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23—Updating
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
    • G06F3/017—Gesture based interaction, e.g. based on a set of recognized hand gestures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/06—Digital input from, or digital output to, record carriers, e.g. RAID, emulated record carriers or networked record carriers
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/16—Sound input; Sound output
    • G06F3/167—Audio in a user interface, e.g. using voice commands for navigating, audio feedback
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements

Landscapes

  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Human Computer Interaction (AREA)
  • Business, Economics & Management (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Accounting & Taxation (AREA)
  • Development Economics (AREA)
  • Finance (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • Health & Medical Sciences (AREA)
  • Economics (AREA)
  • Game Theory and Decision Science (AREA)
  • Software Systems (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Multimedia (AREA)
  • Marketing (AREA)
  • Audiology, Speech & Language Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Information Transfer Between Computers (AREA)
  • Telephonic Communication Services (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods and apparatus are provided for providing advertisements in an advertisement providing apparatus. An advertising audio signal is received and recorded, the recorded advertising audio signal is converted into audio data, and the audio data is stored, at the advertisement providing apparatus. The audio data and targeting purpose data are transmitted from the advertisement providing apparatus to an advertising server. Relevant advertising information is retrieved from among a plurality of advertising information stored in advance in an advertisement Database (DB), using the received audio data and the targeting purpose data. The received advertising information is transmitted from the advertising server to the advertisement providing apparatus. The advertising information is output from the advertisement providing apparatus.

Description

GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA

SYAIS (Kabat)/ GGTFSSY (Chothia) RIIPIFGTANYAQKFQG (Kabat)/ IPIFGT (Chothia) HGGYSFDS (Kabat)/ HGGYSFDS (Chothia) SGDNLGSKYVD (Kabat)/ DNLGSKY (Chothia) SDNNRPS (Kabat)/ SDN (Chothia) ATYDSSPRTE (Kabat)/ YDSSPRTE (Chothia) EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSS

SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVL

EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC
ARHGGYSFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSC

SYVLTQPPSVSVAPGKTARISCSGDNLGSKYVDWYQQKPGQAPVLVIY
SDNNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYDSSPRT
EVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPG
AVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS

SEQ.ID.N0:273 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCA

SEQ.ID.N0:274 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTA

SEQ.ID.N0:275 GAGGTGCAGCTGGTGCAGAGCGGAGCCGAAGTGAAGAAACCCGGCAGC
AGCGTGAAGGTGTCCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTAC
GCCATCAGCTGGGTGCGCCAGGCTCCTGGACAGGGCCTGGAATGGATG
GGCCGGATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAATTC
CAGGGCAGAGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTAC
ATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGT
GCCCGGCACGGCGGCTACAGCTTCGATAGCTGGGGCCAGGGCACCCTG
GTGACCGTGAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTG
GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCA
GGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGT

SEQ.ID.N0:276 AGCTACGTGCTGACTCAGCCCCCTTCTGTGTCTGTGGCCCCTGGCAAG
ACCGCCAGAATCAGCTGCAGCGGCGACAACCTGGGCAGCAAATACGTG
GACTGGTATCAGCAGAAGCCCGGCCAGGCTCCCGTGCTGGTGATCTAC
AGCGACAACAACCGGCCCAGCGGCATCCCTGAGCGGTTCAGCGGCAGC
AACAGCGGCAATACCGCCACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCGCCACCTACGACAGCAGCCCCAGAACC
GAGGTGTTCGGAGGCGGAACAAAGTTAACCGTCCTAGGTCAGCCCAAG
GCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAA
GCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGA
GCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGA
GTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCC
AGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGC
TACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG
GCCCCTACAGAATGTTCA
Human Factor P 401 NP 001138724.1 PVLCFTQYEESSGKCKGLLGGGVSVEDCCLNTAFAYQKRSGGLCQPCR
SPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTLEWQL
QACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGG
HCPGQAQESEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETR
SRKCSAPEPSQKPPGKPCPGLAYEQRRCTGLPPCPVAGGWGPWGPVSP
CPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDATRTHICNTAVPCPVDG
EWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQ
QDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLP
KYPPTVSMVEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPA
CKDPEEEEL
Chimpanzee 402 Factor P MITEGAQAPCLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLG
XP 001136665.1 GGVSVKDCCLNTAYAYQERNGGLCQPCRSPRWSLWSTWAPCSVTCSEG
SQLRYRRCVGWNGQCSERVALGTLEWQLQACEDKQCCPEMGGWSDWGP
WEPCSVTCSKGMRTRRRACNHPAPKCGGHCPGEAQESEACDTQQVCPT
HGAWAAWGPWSPCSGSCHGGPHEPKETRSRTCSAPEPSQKPPGKPCPG
PAYEHRKCTGLPPCPVAGGWGPWGPVSPCPVTCGLGQTIERRTCNRPV
PQHGGPSCAGDATRTHICNTAAPCPVDGEWDLWGQWSTCVRRNMKSIS
CEEIPGQQSRWRTCKGRKFDGHRCTGQQQDIRHCYSIQHCPLKGSWSE
WSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSMVEGQGEKNVTFW
GRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEKL
Rat Factor P 403 NP 001100227.1 MPVGMQAPQWLLLLLLILPTTGSDPVLCFTQYEEPSGRCKGLLGRDIR
VEDCCLNTAYAFQEHDGGLCQSCRSPQWSAWSSWGPCSVTCSEGSQLR
HRRCVGRGGQCSEKAAPGTLEWQLQACEDQLCCPEMGGWSEWGPWGPC
SVTCSKGTQTRQRLCDNPAPKCGGHCPGEAQQSQACDTQKICPTHGAW

ASWGPWSACSGSCLGGAQEPKETRSRSCSAPAPSHQPPGKPCSGTAYE
HRGCSGLPPCPVAGGWGPWGPSSPCPVTCGLGQTLERRTCDHPVPRHG
GPFCAGDATRKHVCNTAMPCPVNGEWEAWGKWSHCSRVRMKSISCDEI
PGQQSRSRSCGGRKFDGQPCTGKLQDIRHCYDIHNCVLKGSWSQWSTW
GLCTPPCGPNPTRVRQRLCTPLLPKYSPTVSMVEGQGEKNVTFWGIPR
PLCEVLQGQKLVVEEKRPCLHVPSCRDPEEKKP
Rabbit Factor P 404 XP 002719931.1 MPAQAQPPLPLLLLPLLLTLPATGADPVVCFTEYDEPSGKCKGLLGGG
VSVEHCCLNAAYAFQEPGSGLCHACRSPLWSPWSAWAPCSVTCSEGSQ
LRHRRCVGQGGPCSEKAAPGTLQWQLQACEDQPCCPEIGGWSDWGPWR
PCSVTCSKGTKTRQRACDRPAPKCGGRCPGEAQESEACDTKQVCPTHG
LWAAWGPWSPCSGSCHGGPQVPKETRSRTCSAPEPSKQPPGKPCSGPA
YEEQSCAGLPPCPVAGGWGPWGPVSSCSVTCGLGKTLEKRTCDHPVPQ
HGGPFCTGDATRTHICNTAVPCPVNGEWEAWGEWSECSRPGRKSI SCE
EVPGQQRRTRVCKGRKFDGQRCAGEYQDIRHCYNIQRCRLKGSWLEWS
SWGLCTPPCGPSPTRTRQRLCTALLPKFPPTISLVEGQGEKNVTFWGK
PWPQCEQLQGQKLVVEEKRPCLHVPACKDPEEKP
Mouse Factor P 405 NP 032849.2 MPAEMQAPQWLLLLLVILPATGSDPVLCFTQYEESSGRCKGLLGRDIR
VEDCCLNAAYAFQEHDGGLCQACRSPQWSAWSLWGPCSVTCSEGSQLR
HRRCVGRGGQCSENVAPGTLEWQLQACEDQPCCPEMGGWSEWGPWGPC
SVTCSKGTQIRQRVCDNPAPKCGGHCPGEAQQSQACDTQKTCPTHGAW
ASWGPWSPCSGSCLGGAQEPKETRSRSCSAPAPSHQPPGKPCSGPAYE
HKACSGLPPCPVAGGWGPWSPLSPCSVTCGLGQTLEQRTCDHPAPRHG
GPFCAGDATRNQMCNKAVPCPVNGEWEAWGKWSDCSRLRMSINCEGTP
GQQSRSRSCGGRKFNGKPCAGKLQDIRHCYNIHNCIMKGSWSQWSTWS
LCTPPCSPNATRVRQRLCTPLLPKYPPTVSMVEGQGEKNVTFWGTPRP
LCEALQGQKLVVEEKRSCLHVPVCKDPEEKKP
TSR5 Domain of 406 SEQ ID NO: 401 VDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRCAGQQQD
IRHCYSIQHCP
Region B of TSR 407 domain PCIRRNMKSISCQEIPGQQSRGR
Region of TSR 5 408 binding domain KSISC
TSR5 Domain of 409 mouse SEQ ID VNGEWEAWGKWSDCSRLRMSINCEGTPGQQSRSRSCGGRKFNGKPCAGKLQDI
NO: 405 RHCYNIHNCI
Table 2 Examples of C5 Antibodies, Fabs and C5 Proteins Antibody 8109 Sequence Identifier (SEQ ID NO:) SYAIS

GIGPFFGTANYAQKFQG

DTPYFDY

SGDSIPNYYVY

DDSNRPS

QSFDSSLNAEV

EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISVVVRQAPGQGLEWMGGIGPFFGTANYAQKFQG
RVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS

SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGN
TATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL
Heavy chain 418 EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISVVVRQAPGQGLEWMGGIGPFFGTANYAQKFQG
RVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPI EKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Light chain 419 SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGN
TATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVC
LISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSN NKYAASSYLSLTPEQWKSHRSYSCQVTHEGST
VEKTVAPTECS
PN encoding 420 SEQ ID GAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTGAAAGTGAGCT
NO:416 GCAAAGCCTCCGGAGGCACTTTTTCTTCTTATGCCATTTCTTGGGTGCGCCAAGCCCCTGGGCAG
GGTCTCGAGTGGATGGGCGGTATCGGTCCGTTTTTTGGCACTGCGAATTACGCGCAGAAGTTTCA
GGGCCGGGTGACCATTACCGCGGATGAAAGCACCAGCACCGCGTATATGGAACTGAGCAGCCTG
CGTAGCGAAGATACGGCCGTGTATTATTGCGCGCGTGATACTCCTTATTTTGATTATTGGGGCCA
AGGCACCCTGGTGACGGTTAGCTCA
PN encoding 421 SEQ ID TCCTATGAACTCACACAGCCCCTGAGCGTGAGCGTGGCCCTGGGCCAGACCGCCCGGATCACCT
NO:417 GCTCCGGCGACAGCATCCCCAACTACTACGTGTACTGGTACCAGCAGAAGCCCGGCCAGGCCCC
CGTGCTGGTGATCTACGACGACAGCAACCGGCCCAGCGGCATCCCCGAGCGGTTCAGCGGCAG
CAACAGCGGCAACACCGCCACCCTGACCATTTCCAGAGCACAGGCAGGCGACGAGGCCGACTA
CTACTGCCAGAGCTTCGACAGCAGCCTGAACGCCGAGGTGTTCGGCGGAGGGACCAAGTTAACC
GTCCTA
PN encoding 422 SEQ ID GAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTGAAAGTGAGCT
NO:418 GCAAAGCCTCCGGAGGCACTTTTTCTTCTTATGCCATTTCTTGGGTGCGCCAAGCCCCTGGGCAG
GGTCTCGAGTGGATGGGCGGTATCGGTCCGTTTTTTGGCACTGCGAATTACGCGCAGAAGTTTCA
GGGCCGGGTGACCATTACCGCGGATGAAAGCACCAGCACCGCGTATATGGAACTGAGCAGCCTG
CGTAGCGAAGATACGGCCGTGTATTATTGCGCGCGTGATACTCCTTATTTTGATTATTGGGGCCA
AGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG
TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGG
CACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGG
GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC
GGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC

CGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC
AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC
ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 423 SEQ ID TCCTATGAACTCACACAGCCCCTGAGCGTGAGCGTGGCCCTGGGCCAGACCGCCCGGATCACCT
NO:419 GCTCCGGCGACAGCATCCCCAACTACTACGTGTACTGGTACCAGCAGAAGCCCGGCCAGGCCCC
CGTGCTGGTGATCTACGACGACAGCAACCGGCCCAGCGGCATCCCCGAGCGGTTCAGCGGCAG
CAACAGCGGCAACACCGCCACCCTGACCATTTCCAGAGCACAGGCAGGCGACGAGGCCGACTA
CTACTGCCAGAGCTTCGACAGCAGCCTGAACGCCGAGGTGTTCGGCGGAGGGACCAAGTTAACC
GTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTC
AAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGC
CTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAG
CAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGA
AGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAAT
GTTCA
Optimized PN 424 encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGTAGCAGCGTCAAGGTGTCC
ID NO:418 TGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGCCATCAGCTGGGTGCGGCAGGCCCCAGGC
CAGGGCCTGGAGTGGATGGGCGGCATCGGCCCATTCTTCGGCACCGCCAACTACGCCCAGAAG
TTCCAGGGCAGGGTCACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGTCCA
GCCTGAGAAGCGAGGACACCGCCGTGTACTACTGCGCCAGAGACACCCCCTACTTCGACTACTG
GGGCCAGGGCACCCTGGTGACCGTGAGCAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCT
GGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTT
CCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCAG
CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGAA
GCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCA
GGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACA
ACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGA
ATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGCC
AAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAAG
AACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCA
GCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCAG
CTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACCC
GGCAAG
Optimized PN 425 encoding SEQ AGCTACGAGCTGACCCAGCCCCTGAGCGTGAGCGTGGCCCTGGGCCAGACCGCCAGGATCACC
ID NO:419 TGCAGCGGCGACAGCATCCCCAACTACTACGTGTACTGGTATCAGCAGAAGCCCGGCCAGGCCC
CCGTGCTGGTGATCTACGACGACAGCAACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCA
GCAACAGCGGCAACACCGCCACCCTGACCATCAGCAGAGCCCAGGCCGGCGACGAGGCCGACT
ACTACTGCCAGAGCTTCGACAGCTCACTGAACGCCGAGGTGTTCGGCGGAGGGACCAAGCTGAC
CGTGCTGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCT
GCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG
GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAG
AGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACA

GGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCG
AGTGCAGC
Antibody 8110 Sequence Identifier (SEQ ID NO:) and Sequence or comments NYIS

II DPDDSYTEYS PSFQG

YEYGGFDI

SGDNIGNSYVH

KDNDRPS

GTYDIESYV

EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISVVVRQM PGKGL EWMGI I DP DDSYTEYSPSFQGQV
TISADKSISTAYLQWSSLKASDTAMYYCARYEYGGFDIWGQGTLVTVSS

SYELTQPPSVSVAPGQTARISCSGDNIGNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCGTYDIESYVFGGGTKLTVL
Heavy chain 434 EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISVVVRQM PGKGL EWMGI I DP DDSYTEYSPSFQGQV
TISADKSISTAYLQWSSLKAS DTAMYYCARYEYGGFDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYF PEPVTVSWNSGALTS GVHTFPAVLQSS GLYSLSSVVTVPSSS LGTQTYICNVN H
KPS NTKVDKRVE PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPE
VKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
S KLTVD KS RWQQGNVFSCSVM H EALHN HYTQ KS LS LS PGK
Light chain 435 SYELTQPPSVSVAPGQTARISCSGDNIGNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCGTYDIESYVFGGGTKLTVLGQPKAAPSVTLFPPSSE ELQAN KATLVCL IS
DFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTH EGSTVE
KTVAPTECS
PN encoding 436 SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:432 GCAAAGGTTCCGGATATTCCTTTACTAATTATATTTCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATTGATCCTGATGATTCTTATACTGAGTATTCTCCTTCTTTTCAGGGT
CAGGTCACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAGC
GAGCGATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGTTTTGATATTTGGGGCCAAG
GCACCCTGGTGACGGTTAGCTCA
PN encoding 437 SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
NO:434 GTAGCGGCGATAATATTGGTAATTCTTATGTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCGGTACTTATGATATTGAGTCTTATGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTA
PN encoding 438 SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT

NO:435 GCAAAGGTTCCGGATATTCCTTTACTAATTATATTTCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATTGATCCTGATGATTCTTATACTGAGTATTCTCCTTCTTTTCAGGGT
CAGGTCACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAGC
GAGCGATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGTTTTGATATTTGGGGCCAAG
GCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTC
CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC
CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCA
CCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGA
GCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGGGA
CCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGT
CACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGG
GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG
TCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG
AGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTG
ACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGC
CGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 439 SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAG CGTTG CACCAG GTCAGACCG CG CGTATCTC
GT
NO:436 GTAGCGGCGATAATATTGGTAATTCTTATGTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCGGTACTTATGATATTGAGTCTTATGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGGTCAG
CCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGG
CCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGA
TAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTAC
GCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCC
AGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
Optimized PN 440 encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAAAAGCCCGGTGAGAGCCTGAAGATCAGC
ID NO:434 TGCAAGGGCAGCGGCTACAGCTTCACCAACTACATCAGCTGGGTGCGGCAGATGCCCGGCAAG
GGCCTGGAGTGGATGGGCATCATCGACCCCGACGACAGCTACACCGAGTACAGCCCCAGCTTCC
AGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCC
TGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGATACGAGTACGGCGGCTTCGACATCTG
GGGCCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCT
GGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTT
CCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCAG
CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGAA
GCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCA
GGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACA
ACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGA
ATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGCC
AAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAAG
AACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG

AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCA
GCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCAG
CTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACCC
GGCAAG
Optimized PN 441 encoding SEQ AGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCAGGCCAGACCGCCAGGATCAGC
ID NO:435 TGCAGCGGCGACAACATCGGCAACAGCTACGTGCACTGGTATCAGCAGAAGCCCGGCCAGGCC
CCCGTGCTGGTGATCTACAAGGACAACGACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGC
AGCAACTCCGGCAACACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAGGACGAGGCCGAC
TACTACTGCGGCACCTACGACATCGAGTCATACGTGTTCGGCGGAGGGACCAAGCTGACCGTGC
TGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCTGCAGG
CCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGGCCTG
GAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGCAA
CAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTC
CTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTG
CAGC
Antibody 8111 Sequence Identifier (SEQ ID NO:) and Sequence or comments TSGGGVS

NIDDADIKDYSPSLKS

GPYGFDS

TGTSSDI GTYNYVS

DDSNRPS

QSYDSQSIV

EVTLKESGPALVKPTQTLTLTCTFSGFSLSTS GGGVSWI RQP PGKAL EWLAN I DDADI KDYSPSL KS RL

TISKDTSKNQVVLTMTNM DPVDTATYYCARGPYGFDSWGQGTLVTVSS

ESALTQPASVS GS PGQSITISCTGTSSDI GTYNYVSWYQQH PGKAPKLM IYDDS NRPSGVSN RFSGSK
SGNTASLTISGLQAEDEADYYCQSYDS QS IVFGGGTKLTVL
Heavy chain 450 EVTLKESGPALVKPTQTLTLTCTFSGFSLSTS GGGVSWI RQP PGKAL EWLAN I DDADI KDYSPSL KS RL

TISKDTSKNQVVLTMTNM DPVDTATYYCARGPYGFDSWGQGTLVTVSSASTKGPSVFPLAPSS KSTS
GGTAALGCLVKDYF PEPVTVSWNSGALTS GVHTFPAVLQSS GLYSLSSVVTVPSSS LGTQTYI CNVN H
KPS NTKVDKRVE PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPE
VKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVD KS RWQQGNVFSCSVM H EALH N HYTQ KS LS LS PGK
Light chain 451 ESALTQPASVS GS PGQSITISCTGTSSDI GTYNYVSWYQQH PGKAPKLM IYDDS NRPSGVSN RFSGSK
SGNTASLTIS GLQAEDEADYYCQSYDSQSIVFGGGTKLTVLGQ PKAAPSVTLF PPSS EELQAN KATLV
CL IS D FYPGAVTVAWKADSS PVKAGVETTTPS KQSN N KYAASSYLS LTPEQWKSH RSYSCQVTH E GS

TVEKTVAPTECS
PN encoding 452 SEQ ID GAGGTGACATTGAAAGAAAGCGGCCCGGCCCTGGTGAAACCGACCCAAACCCTGACCCTGACCT

NO:448 GTACCTTTTCCGGATTTAGCCTGTCTACTTCTGGTGGTGGTGTGTCTTGGATTCGCCAGCCGCCT
GGGAAAGCCCTCGAGTGGCTGGCTAATATTGATGATGCTGATATTAAGGATTATTCTCCTTCTCTT
AAGTCTCGTCTGACCATTAGCAAAGATACTTCGAAAAATCAGGTGGTGCTGACTATGACCAACATG
GACCCGGTGGATACGGCCACCTATTATTGCGCGCGTGGTCCTTATGGTTTTGATTCTTGGGGCCA
AGGCACCCTGGTGACGGTTAGCTCA
PN encoding 453 SEQ ID GAAAGCGCACTGACCCAGCCAGCTTCAGTGAGCGGCTCACCAGGTCAGAGCATTACCATCTCGT
NO:449 GTACGGGTACTAGCAGCGATATTGGTACTTATAATTATGTGTCTTGGTACCAGCAGCATCCCGGG
AAGGCGCCGAAACTTATGATTTATGATGATTCTAATCGTCCCTCAGGCGTGAGCAACCGTTTTAGC
GGATCCAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAAGCGGAAGACGAAGCG
GATTATTATTGCCAGTCTTATGATTCTCAGTCTATTGTGTTTGGCGGCGGCACGAAGTTAACCGTC
CTA
PN encoding 454 SEQ ID GAGGTGACATTGAAAGAAAGCGGCCCGGCCCTGGTGAAACCGACCCAAACCCTGACCCTGACCT
NO:450 GTACCTTTTCCGGATTTAGCCTGTCTACTTCTGGTGGTGGTGTGTCTTGGATTCGCCAGCCGCCT
GGGAAAGCCCTCGAGTGGCTGGCTAATATTGATGATGCTGATATTAAGGATTATTCTCCTTCTCTT
AAGTCTCGTCTGACCATTAGCAAAGATACTTCGAAAAATCAGGTGGTGCTGACTATGACCAACATG
GACCCGGTGGATACGGCCACCTATTATTGCGCGCGTGGTCCTTATGGTTTTGATTCTTGGGGCCA
AGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG
TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGG
CACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGG
GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC
GGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC
CGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC
AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC
ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 455 SEQ ID GAAAGCGCACTGACCCAGCCAGCTTCAGTGAGCGGCTCACCAGGTCAGAGCATTACCATCTCGT
NO:451 GTACGGGTACTAGCAGCGATATTGGTACTTATAATTATGTGTCTTGGTACCAGCAGCATCCCGGG
AAGGCGCCGAAACTTATGATTTATGATGATTCTAATCGTCCCTCAGGCGTGAGCAACCGTTTTAGC
GGATCCAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAAGCGGAAGACGAAGCG
GATTATTATTGCCAGTCTTATGATTCTCAGTCTATTGTGTTTGGCGGCGGCACGAAGTTAACCGTC
CTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAG
CCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTG
GAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAAC
AACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCT
ACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTC
A
Optimized PN 456 encoding SEQ GAGGTGACCCTGAAGGAGAGCGGCCCAGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACT
ID NO:448 TGCACCTTCAGCGGCTTCAGCCTGAGCACCAGCGGAGGGGGCGTGAGCTGGATCAGGCAGCCC
CCAGGTAAGGCCCTGGAGTGGCTGGCCAATATCGACGACGCCGATATCAAGGACTACAGCCCCA

GCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGACCATGAC
CAATATGGACCCCGTGGACACCGCCACCTACTACTGCGCCAGAGGCCCCTACGGCTTCGACAGC
TGGGGCCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCC
CTGGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGAC
TACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCT
TCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCA
GCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGA
CAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGA
AGCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGC
AGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTC
AACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTAC
AACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAG
AATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGC
CAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAA
GAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGC
AGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCA
GCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACC
CGGCAAG
Optimized PN 457 encoding SEQ GAGAGCGCCCTGACCCAGCCCGCCAGCGTGAGCGGCAGCCCAGGCCAGTCTATCACAATCAGC
ID NO:449 TGCACCGGCACCTCCAGCGATATCGGCACCTACAACTACGTGAGCTGGTATCAGCAGCACCCCG
GCAAGGCCCCCAAGCTGATGATCTACGACGACAGCAACAGGCCCAGCGGCGTGAGCAACAGGTT
CAGCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACAATCAGCGGCCTGCAGGCCGAGGACGA
GGCCGACTACTACTGCCAGAGCTACGACAGCCAGTCAATCGTGTTCGGCGGAGGGACCAAGCTG
ACCGTGCTGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAG
CTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCG
TGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGC
AGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCA
CAGGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAAC
CGAGTGCAGC
Antibody 8113 Sequence Identifier (SEQ ID NO:) and Sequence or comments CDRH1 SEQ ID NO:426 II DPDDSYTRYSPSFQG
CDRH3 SEQ ID NO:428 CDRL1 SEQ ID NO:429 CDRL2 SEQ ID NO:430 ATWGSEDQV

EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISVVVRQM PGKGL EWM GII D PD DSYTRYS PS FQGQV
TISADKSISTAYLQWSSLKASDTAMYYCARYEYGGFDIWGQGTLVTVSS

SYELTQPPSVSVAPGQTARISCSGDNIGNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCATWGSEDQVFGGGTKLTVL
Heavy chain 462 EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYISVVVRQM PGKGL EWM GII D PD DSYTRYS PS FQGQV
TISADKSISTAYLQWSSLKAS DTAMYYCARYEYGGFDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH

KPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Light chain 463 SYELTQPPSVSVAPGQTARISCSGDNIGNSYVHWYQQKPGQAPVLVIYKDNDRPSGIPERFSGSNSG
NTATLTISGTQAEDEADYYCATWGSEDQVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCL
IS DFYPGAVTVAWKADSSPVKAGVETTTPS KQSN NKYAASSYLSLTPEQWKSH RSYSCQVTHEGSTV
EKTVAPTECS
PN encoding 464 SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:460 GCAAAGGTTCCGGATATTCCTTTACTAATTATATTTCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATCGATCCGGATGATAGCTATACCCGTTATTCTCCGAGCTTTCAGGG
ACAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAG
CGAGCGATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGTTTTGATATTTGGGGCCAA
GGCACCCTGGTGACGGTTAGCTCA
PN encoding 465 SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
NO:461 GTAGCGGCGATAATATTGGTAATTCTTATGTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCGCTACTTGGGGTTCTGAGGATCAGGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTA
PN encoding 466 SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:462 GCAAAGGTTCCGGATATTCCTTTACTAATTATATTTCTTGGGTGCGCCAGATGCCTGGGAAGGGT
CTCGAGTGGATGGGCATTATCGATCCGGATGATAGCTATACCCGTTATTCTCCGAGCTTTCAGGG
ACAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAAAG
CGAGCGATACGGCCATGTATTATTGCGCGCGTTATGAGTATGGTGGTTTTGATATTTGGGGCCAA
GGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCT
CCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG
AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTG
TCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGG
CACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT
GAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGGG
GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAG
GTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC
GGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA
GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCC
CGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCC
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA
GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC
AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGC
ATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 467 SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
NO:463 GTAGCGGCGATAATATTGGTAATTCTTATGTTCATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATGATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCGCTACTTGGGGTTCTGAGGATCAGGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGGTCA

GCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAG
GCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAG
ATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTA
CGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGC
CAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
Optimized PN 468 encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAAAAGCCCGGTGAGAGCCTGAAGATCAGC
ID NO:462 TGCAAGGGCAGCGGCTACAGCTTCACCAACTACATCAGCTGGGTGCGGCAGATGCCCGGCAAG
GGCCTGGAGTGGATGGGCATCATCGACCCCGACGACAGCTACACCAGGTACAGCCCCAGCTTCC
AGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCC
TGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGATACGAGTACGGCGGCTTCGACATCTG
GGGCCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCT
GGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTT
CCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAGCAG
CAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCCGAA
GCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCA
GGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGTTCA
ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACA
ACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGA
ATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAGGCC
AAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACCAAG
AACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCA
GCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTTCAG
CTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCACCC
GGCAAG
Optimized PN 469 encoding SEQ AGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCAGGCCAGACCGCCAGGATCAGC
ID NO:463 TGCAGCGGCGACAATATCGGCAACAGCTACGTGCACTGGTATCAGCAGAAGCCCGGCCAGGCCC
CCGTGCTGGTGATCTACAAGGACAACGACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCA
GCAACTCCGGCAACACCGCCACCCTGACAATCAGCGGCACCCAGGCCGAGGACGAGGCCGACT
ACTACTGCGCCACCTGGGGCTCAGAGGACCAGGTGTTCGGCGGAGGGACCAAGCTGACCGTGC
TGGGCCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCTGCAGG
CCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGGCCTG
GAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGCAA
CAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTC
CTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTG
CAGC
Antibody 8114 Sequence Identifier (SEQ ID NO:) and Sequence or comments SYYI G

II DPTDS QTAYS PS FQG

YMMRGFDH

SGDSLGDYYAY

KDNNRPS

QTWDTGESGV

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYIGVVVRQM PGKGLEWMGIIDPTDSQTAYS PSFQGQ
VTISADKSISTAYLQWSSLKAS DTAMYYCARYMMRGFDHWGQGTLVTVSS

SYELTQPPSVSVAPGQTARISCSGDSLGDYYAYWYQQKPGQAPVLVIYKDN N RPS GI PE RFSGSNSG
NTATLTISGTQAEDEADYYCQTWDTGESGVFGGGTKLTVL
Heavy chain 478 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYIGVVVRQM PGKGLEWMGIIDPTDSQTAYS PSFQGQ
VTISADKSISTAYLQWSSLKAS DTAMYYCARYMM RGFDHWGQGTLVTVSSASTKGPSVFPLAPSSKS
TS GGTAALGCLVKDYFPE PVTVSWNS GALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYI CNV
NH KPS NTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH E
DPEVKFNWYVDGVEVH NAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTI
SKAKGQP RE PQVYTLP PSRE E MTKN QVSLTC LVKGFYPSDIAVEWESN GQ PE N NYKTTPPVLDSDGS

FF LYS KLTVD KS RWQQGNVFSCSVM H EALH N HYTQ KS LS LS PGK
Light chain 479 SYE LTQPPSVSVAPGQTARISCSGDS LGDYYAYWYQQKPGQAPVLVIYKDN N RPSGI PE RFSGS NS G
NTATLTISGTQAEDEADYYCQTWDTGESGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLV
CLISDFYPGAVTVAWKADSS PVKAGVETTTPSKQSN N KYAASSYLSLTPEQWKSH RSYSCQVTH E GS
TVEKTVAPTECS
PN encoding 480 SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:476 GCAAAGGTTCCGGATATTCCTTTACTTCTTATTATATTGGTTGGGTGCGCCAGATGCCTGGGAAG
GGTCTCGAGTGGATGGGCATTATTGATCCTACTGATTCTCAGACTGCTTATTCTCCTTCTTTTCAG
GGTCAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAA
AGCGAGCGATACGGCCATGTATTATTGCGCGCGTTATATGATGCGTGGTTTTGATCATTGGGGCC
AAGGCACCCTGGTGACGGTTAGCTCA
PN encoding 481 SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGT
NO:478 GTAGCGGCGATTCTCTTGGTGATTATTATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCCAGACTTGGGATACTGGTGAGTCTGGTGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTA
PN encoding 482 SEQ ID GAGGTGCAATTGGTTCAGAGCGGCGCGGAAGTGAAAAAACCGGGCGAAAGCCTGAAAATTAGCT
NO:479 GCAAAGGTTCCGGATATTCCTTTACTTCTTATTATATTGGTTGGGTGCGCCAGATGCCTGGGAAG
GGTCTCGAGTGGATGGGCATTATTGATCCTACTGATTCTCAGACTGCTTATTCTCCTTCTTTTCAG
GGTCAGGTGACCATTAGCGCGGATAAAAGCATTAGCACCGCGTATCTTCAATGGAGCAGCCTGAA
AGCGAGCGATACGGCCATGTATTATTGCGCGCGTTATATGATGCGTGGTTTTGATCATTGGGGCC
AAGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACC
CTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCT
GTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGG
GCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGT
TGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCGGGG
GGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGA
GGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTG

GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC
CGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCA
AGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGC
CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA
CAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
PN encoding 483 SEQ ID AGTTACGAACTGACCCAGCCGCCTTCAGTGAG CGTTG CACCAG GTCAGACCG CG CGTATCTC
GT
NO:480 GTAGCGGCGATTCTCTTGGTGATTATTATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCA
GTTCTTGTGATTTATAAGGATAATAATCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAAC
AGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATT
GCCAGACTTGGGATACTGGTGAGTCTGGTGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGG
TCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAAC
AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGG
CAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAA
GTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGC
TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA
Optimized PN 484 encoding SEQ GAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAAAAGCCCGGTGAGAGCCTGAAGATCAGC
ID NO:479 TGCAAGGGCAGCGGCTACAGCTTCACCAGCTACTACATCGGCTGGGTGCGGCAGATGCCCGGC
AAGGGCCTGGAGTGGATGGGCATCATCGACCCCACCGACAGCCAGACCGCCTACAGCCCCAGC
TTCCAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCA
GCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCCGGTACATGATGAGGGGCTTCGACCA
CTGGGGTCAGGGCACCCTGGTGACCGTCAGCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCC
CCTGGCCCCCAGCAGCAAGAGCACCTCCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGA
CTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACAC
CTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTCCAGCGTGGTGACAGTGCCCAG
CAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTG
GACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCCCCC
GAAGCTGCAGGCGGCCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCA
GCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAGAGGTGAAGT
TCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGT
ACAACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAA
AGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCTGCCCCCATCGAAAAGACCATCAGCAAG
GCCAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCTTCTCGGGAGGAGATGACC
AAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGT
GGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACG
GCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTGTT
CAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCA
CCCGGCAAG
Optimized PN 485 encoding SEQ AGCTACGAGCTGACCCAGCCCCCCAGCGTGAGCGTGGCCCCAGGCCAGACCGCCAGGATCAGC
ID NO:480 TGCAGCGGCGACAGCCTGGGCGACTACTACGCCTACTGGTATCAGCAGAAGCCCGGCCAGGCC
CCCGTGCTGGTGATCTACAAGGACAACAACAGGCCCAGCGGCATCCCCGAGAGGTTCAGCGGCA
GCAACAGCGGCAACACCGCCACCCTGACAATCAGCGGCACCCAGGCCGAGGACGAGGCCGACT
ACTACTGCCAGACCTGGGACACCGGCGAGTCAGGCGTGTTCGGCGGAGGGACCAAGCTGACCG
TGCTGGGTCAGCCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGAGCTGC
AGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTGGC

CTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAG
CAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAG
GTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGA
GTGCAGC
Other antibodies of the invention include those where the amino acids or nucleic acids encoding the amino acids have been mutated, yet have at least 60, 65, 70, 75, 80, 85, 90, or 95 percent identity to the sequences described in Table 1. Some embodiments include mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated in the variable regions when compared with the variable regions depicted in the sequence described in Table 1, while retaining substantially the same antigen binding activity.
Since each of these antibodies can bind to Factor P, the VH, VL, full length light chain, and full length heavy chain sequences (amino acid sequences and the nucleotide sequences encoding the amino acid sequences) can be "mixed and matched" to create other Factor P-binding antibodies of the invention. Such "mixed and matched"
Factor P-binding antibodies can be tested using the binding assays known in the art (e.g., ELISAs, and other assays described in the Example section). When these chains are mixed and matched, a VH sequence from a particular VH/VL pairing should be replaced with a structurally similar VH sequence. Likewise a full length heavy chain sequence from a particular full length heavy chain / full length light chain pairing should be replaced with a structurally similar full length heavy chain sequence. Likewise, a VL sequence from a particular VH/VL pairing should be replaced with a structurally similar VL
sequence.
Likewise a full length light chain sequence from a particular full length heavy chain / full length light chain pairing should be replaced with a structurally similar full length light chain sequence. Accordingly, in one aspect, the invention provides an isolated antibody or antigen binding region thereof having: a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7,21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 and 273, and a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, and 274 wherein the antibody specifically binds to Factor P
(e.g., human and/or cynomolgus Factor P).
In another aspect, the invention provides (i) an isolated antibody having: a full length heavy chain comprising an amino acid sequence that has been optimized for expression in a mammalian cell selected from the group consisting of SEQ ID
NOs: 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219, 233, 247, 261 and 275, and a full length light chain comprising an amino acid sequence that has been optimized for expression in a mammalian cell selected from the group consisting of SEQ
ID NOs: 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262 and 276; or (ii) a functional protein comprising an antigen binding portion thereof.
The terms "complementarity determining region," and "CDR," as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3).
The precise amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 ("Chothia" numbering scheme).
For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-(HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). By combining the CDR definitions of both Kabat and Chothia, the CDRs consist of amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in human VH and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in human VL.
In another aspect, the present invention provides Factor P binding antibodies that comprise the heavy chain and light chain CDR1s, CDR2s, and CDR3s as described in Table 1, or combinations thereof. The amino acid sequences of the VH CDR1s of the antibodies are shown in SEQ ID NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, or 267. The amino acid sequences of the VH
CDR2s of the antibodies and are shown in SEQ ID NOs: 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, or 268. The amino acid sequences of the VH CDR3s of the antibodies are shown in SEQ ID NOs: 3, 17, 31, 45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185, 199, 213, 227, 241, 255, or 269. The amino acid sequences of the VL CDR1s of the antibodies are shown in SEQ ID NOs: 4, 18, 32, 46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186, 200, 214, 228, 242, 256, or 270. The amino acid sequences of the VL CDR2s of the antibodies are shown in SEQ ID
NOs: 5, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187, 201, 215, 229, 243, 257, or 271. The amino acid sequences of the VL CDR3s of the antibodies are shown in SEQ
ID NOs: 6, 20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174, 188, 202, 216, 230, 244, 258, or 272. These CDR regions are delineated using the Kabat system.
Alternatively, as defined using the Chothia system (Al-Lazikani et al., (1997) JMB
273,927-948) the amino acid sequences of the VH CDR1s of the antibodies are shown in SEQ ID NOs: 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 365, 371, 377, 383, 389, or 395. The amino acid sequences of the VH CDR2s of the antibodies and are shown in SEQ ID NOs: 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 360, 366, 372, 378, 384, 390, or 396. The amino acid sequences of the VH CDR3s of the antibodies are shown in SEQ ID NOs: 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 361, 367, 373, 379, 385, 391, or 397.
The amino acid sequences of the VL CDR1s of the antibodies are shown in SEQ ID
NOs:
284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 362, 368, 374, 380, 386, 392, or 398. The amino acid sequences of the VL CDR2s of the antibodies are shown in SEQ ID NOs: 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, or 399. The amino acid sequences of the VL CDR3s of the antibodies are shown in SEQ ID NOs: 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, or 400.
Given that each of these antibodies can bind to Factor P and that antigen-binding specificity is provided primarily by the CDR1, 2 and 3 regions, the VH CDR1, 2 and 3 sequences and VL CDR1, 2 and 3 sequences can be "mixed and matched" (i.e., CDRs from different antibodies can be mixed and matched, although each antibody preferably contains a VH CDR1, 2 and 3 and a VL CDR1, 2 and 3 to create other Factor P
binding binding molecules of the invention. Such "mixed and matched" Factor P binding antibodies can be tested using the binding assays known in the art and those described in the Examples (e.g., ELISAs, SET, Biacore). When VH CDR sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a particular VH sequence should be replaced with a structurally similar CDR sequence(s). Likewise, when VL CDR
sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a particular VL sequence should be replaced with a structurally similar CDR
sequence(s).
It will be readily apparent to the ordinarily skilled artisan that novel VH
and VL sequences can be created by substituting one or more VH and/or VL CDR region sequences with structurally similar sequences from the CDR sequences shown herein for monoclonal antibodies of the present invention. In addition to the foregoing, in one embodiment, the antigen binding fragments of the antibodies described herein can comprise a VH
CDR1, 2, and 3, or a VL CDR 1, 2, and 3, wherein the fragment binds to Factor P as a single variable domain.
In certain embodiments of the invention, the antibodies or antigen binding fragments thereof may have the heavy and light chain sequences of the Fabs described in Table 1. More specifically, the antibody or antigen binding fragment thereof may have the heavy and light sequence of Fab NVS962, NVS963, NVS964, NVS965, NVS966, NVS967, NVS805, NVS806, NVS807, NVS808, NVS809, NVS962-S, NVS962-Q, NVS962-S31A, NVS962-G, NVS962-T, NVS965-S, NVS965-T, or NVS965-Q.
In other enbodiments of the invention the antibody or antigen binding fragment in that specifically binds Factor P comprises a heavy chain variable region CDR1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 as defined by Kabat and described in Table 1. In still other embodiments of the invention the antibody or antigen binding fragment in that specifically binds Factor P
comprises a heavy chain variable region CDR1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 as defined by Chothia and described in Table 1.
In a specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID
NO:1; a heavy chain variable region CDR2 of SEQ ID NO: 2; a heavy chain variable region CDR3 of SEQ ID NO: 3; a light chain variable region CDR1 of SEQ ID NO: 4; a light chain variable region CDR2 of SEQ ID NO: 5; and a light chain variable region CDR3 of SEQ
ID NO: 6. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID
NO: 15; a heavy chain variable region CDR2 of SEQ ID NO: 16; a heavy chain variable region CDR3 of SEQ ID NO: 17; a light chain variable region CDR1 of SEQ ID NO:
18; a light chain variable region CDR2 of SEQ ID NO: 19; and a light chain variable region CDR3 of SEQ ID NO: 20. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 29; a heavy chain variable region CDR2 of SEQ ID NO: 30; a heavy chain variable region CDR3 of SEQ ID NO: 31; a light chain variable region CDR1 of SEQ ID NO: 32; a light chain variable region CDR2 of SEQ ID NO: 33; and a light chain variable region CDR3 of SEQ ID NO: 34. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 46; a light chain variable region CDR2 of SEQ ID
NO: 47; and a light chain variable region CDR3 of SEQ ID NO: 48. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 57; a heavy chain variable region CDR2 of SEQ ID NO: 58; a heavy chain variable region CDR3 of SEQ ID
NO: 59; a light chain variable region CDR1 of SEQ ID NO: 60; a light chain variable region CDR2 of SEQ ID NO: 61; and a light chain variable region CDR3 of SEQ ID
NO:
62. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
71; a heavy chain variable region CDR2 of SEQ ID NO: 72; a heavy chain variable region CDR3 of SEQ ID NO: 73; a light chain variable region CDR1 of SEQ ID NO: 74; a light chain variable region CDR2 of SEQ ID NO: 75; and a light chain variable region CDR3 of SEQ ID NO: 76. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID
NO: 85; a heavy chain variable region CDR2 of SEQ ID NO: 86; a heavy chain variable region CDR3 of SEQ ID NO: 87; a light chain variable region CDR1 of SEQ ID NO:
88; a light chain variable region CDR2 of SEQ ID NO: 89; and a light chain variable region CDR3 of SEQ ID NO: 90. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 99; a heavy chain variable region CDR2 of SEQ ID NO: 100; a heavy chain variable region CDR3 of SEQ ID NO: 101; a light chain variable region CDR1 of SEQ ID NO: 102; a light chain variable region CDR2 of SEQ ID NO: 103;
and a light chain variable region CDR3 of SEQ ID NO: 104. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 113; a heavy chain variable region CDR2 of SEQ ID NO: 114; a heavy chain variable region CDR3 of SEQ ID NO: 115; a light chain variable region CDR1 of SEQ ID NO: 116; a light chain variable region CDR2 of SEQ ID
NO: 117; and a light chain variable region CDR3 of SEQ ID NO: 118. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 127; a heavy chain variable region CDR2 of SEQ ID NO: 128; a heavy chain variable region CDR3 of SEQ

ID NO: 129; a light chain variable region CDR1 of SEQ ID NO: 130; a light chain variable region CDR2 of SEQ ID NO: 131; and a light chain variable region CDR3 of SEQ
ID NO:
132. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
141; a heavy chain variable region CDR2 of SEQ ID NO: 142; a heavy chain variable region CDR3 of SEQ ID NO: 143; a light chain variable region CDR1 of SEQ ID NO: 144;
a light chain variable region CDR2 of SEQ ID NO: 145; and a light chain variable region CDR3 of SEQ ID NO: 146. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 155; a heavy chain variable region CDR2 of SEQ ID NO: 156; a heavy chain variable region CDR3 of SEQ ID NO: 157; a light chain variable region CDR1 of SEQ ID NO: 158; a light chain variable region CDR2 of SEQ ID NO: 159; and a light chain variable region CDR3 of SEQ ID NO: 160. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 169; a heavy chain variable region CDR2 of SEQ ID NO: 170; a heavy chain variable region CDR3 of SEQ ID NO: 171; a light chain variable region CDR1 of SEQ ID NO: 172; a light chain variable region CDR2 of SEQ ID
NO: 173; and a light chain variable region CDR3 of SEQ ID NO: 174. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 183; a heavy chain variable region CDR2 of SEQ ID NO: 184; a heavy chain variable region CDR3 of SEQ
ID NO: 185; a light chain variable region CDR1 of SEQ ID NO: 186; a light chain variable region CDR2 of SEQ ID NO: 187; and a light chain variable region CDR3 of SEQ
ID NO:
188. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
197; a heavy chain variable region CDR2 of SEQ ID NO: 198; a heavy chain variable region CDR3 of SEQ ID NO: 199; a light chain variable region CDR1 of SEQ ID NO: 200;
a light chain variable region CDR2 of SEQ ID NO: 201; and a light chain variable region CDR3 of SEQ ID NO: 202. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 211; a heavy chain variable region CDR2 of SEQ ID NO: 212; a heavy chain variable region CDR3 of SEQ ID NO: 213; a light chain variable region CDR1 of SEQ ID NO: 214; a light chain variable region CDR2 of SEQ ID NO: 215; and a light chain variable region CDR3 of SEQ ID NO: 216. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 225; a heavy chain variable region CDR2 of SEQ ID NO: 226; a heavy chain variable region CDR3 of SEQ ID NO: 227; a light chain variable region CDR1 of SEQ ID NO: 228; a light chain variable region CDR2 of SEQ ID
NO: 229; and a light chain variable region CDR3 of SEQ ID NO: 230. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 239; a heavy chain variable region CDR2 of SEQ ID NO: 240; a heavy chain variable region CDR3 of SEQ
ID NO: 241; a light chain variable region CDR1 of SEQ ID NO: 242; a light chain variable region CDR2 of SEQ ID NO: 243; and a light chain variable region CDR3 of SEQ
ID NO:
244. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
253; a heavy chain variable region CDR2 of SEQ ID NO: 254; a heavy chain variable region CDR3 of SEQ ID NO: 255; a light chain variable region CDR1 of SEQ ID NO: 256;
a light chain variable region CDR2 of SEQ ID NO: 257; and a light chain variable region CDR3 of SEQ ID NO: 258. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 267; a heavy chain variable region CDR2 of SEQ ID NO: 268; a heavy chain variable region CDR3 of SEQ ID NO: 269; a light chain variable region CDR1 of SEQ ID NO: 270; a light chain variable region CDR2 of SEQ ID NO: 271; and a light chain variable region CDR3 of SEQ ID NO: 271.
In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID
NO: 281; a heavy chain variable region CDR2 of SEQ ID NO: 282; a heavy chain variable region CDR3 of SEQ ID NO: 283; a light chain variable region CDR1 of SEQ ID
NO: 284; a light chain variable region CDR2 of SEQ ID NO: 285; and a light chain variable region CDR3 of SEQ ID NO: 286. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 287; a heavy chain variable region CDR2 of SEQ ID
NO:
288; a heavy chain variable region CDR3 of SEQ ID NO: 289; a light chain variable region CDR1 of SEQ ID NO: 290; a light chain variable region CDR2 of SEQ ID
NO: 291;
and a light chain variable region CDR3 of SEQ ID NO: 292. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 293; a heavy chain variable region CDR2 of SEQ ID NO: 294; a heavy chain variable region CDR3 of SEQ
ID NO: 295; a light chain variable region CDR1 of SEQ ID NO: 296; a light chain variable region CDR2 of SEQ ID NO: 297; and a light chain variable region CDR3 of SEQ
ID NO:
298. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
299; a heavy chain variable region CDR2 of SEQ ID NO: 300; a heavy chain variable region CDR3 of SEQ ID NO: 301; a light chain variable region CDR1 of SEQ ID NO: 302;
a light chain variable region CDR2 of SEQ ID NO: 303; and a light chain variable region CDR3 of SEQ ID NO: 304. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 305; a heavy chain variable region CDR2 of SEQ ID NO: 306; a heavy chain variable region CDR3 of SEQ ID NO: 307; a light chain variable region CDR1 of SEQ ID NO: 308; a light chain variable region CDR2 of SEQ ID NO: 309; and a light chain variable region CDR3 of SEQ ID NO: 310. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 311; a heavy chain variable region CDR2 of SEQ ID NO: 312; a heavy chain variable region CDR3 of SEQ ID NO: 313; a light chain variable region CDR1 of SEQ ID NO: 314; a light chain variable region CDR2 of SEQ ID
NO: 315; and a light chain variable region CDR3 of SEQ ID NO: 316. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 317; a heavy chain variable region CDR2 of SEQ ID NO: 318; a heavy chain variable region CDR3 of SEQ
ID NO: 319; a light chain variable region CDR1 of SEQ ID NO: 320; a light chain variable region CDR2 of SEQ ID NO: 321; and a light chain variable region CDR3 of SEQ
ID NO:
322. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
323; a heavy chain variable region CDR2 of SEQ ID NO: 324; a heavy chain variable region CDR3 of SEQ ID NO: 325; a light chain variable region CDR1 of SEQ ID NO: 326;
a light chain variable region CDR2 of SEQ ID NO: 327; and a light chain variable region CDR3 of SEQ ID NO: 328. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 329; a heavy chain variable region CDR2 of SEQ ID NO: 330; a heavy chain variable region CDR3 of SEQ ID NO: 331; a light chain variable region CDR1 of SEQ ID NO: 332; a light chain variable region CDR2 of SEQ ID NO: 333; and a light chain variable region CDR3 of SEQ ID NO: 334. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 335; a heavy chain variable region CDR2 of SEQ ID NO: 336; a heavy chain variable region CDR3 of SEQ ID NO: 337; a light chain variable region CDR1 of SEQ ID NO: 338; a light chain variable region CDR2 of SEQ ID
NO: 339; and a light chain variable region CDR3 of SEQ ID NO: 340. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 341; a heavy chain variable region CDR2 of SEQ ID NO: 342; a heavy chain variable region CDR3 of SEQ
ID NO: 343; a light chain variable region CDR1 of SEQ ID NO: 344; a light chain variable region CDR2 of SEQ ID NO: 345; and a light chain variable region CDR3 of SEQ
ID NO:
346. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
347; a heavy chain variable region CDR2 of SEQ ID NO: 348; a heavy chain variable region CDR3 of SEQ ID NO: 349; a light chain variable region CDR1 of SEQ ID NO: 350;
a light chain variable region CDR2 of SEQ ID NO: 351; and a light chain variable region CDR3 of SEQ ID NO: 352. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 353; a heavy chain variable region CDR2 of SEQ ID NO: 354; a heavy chain variable region CDR3 of SEQ ID NO: 355; a light chain variable region CDR1 of SEQ ID NO: 356; a light chain variable region CDR2 of SEQ ID NO: 357; and a light chain variable region CDR3 of SEQ ID NO: 358. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 359; a heavy chain variable region CDR2 of SEQ ID NO: 360; a heavy chain variable region CDR3 of SEQ ID NO: 361; a light chain variable region CDR1 of SEQ ID NO: 362; a light chain variable region CDR2 of SEQ ID
NO: 363; and a light chain variable region CDR3 of SEQ ID NO: 364. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 365; a heavy chain variable region CDR2 of SEQ ID NO: 366; a heavy chain variable region CDR3 of SEQ
ID NO: 367; a light chain variable region CDR1 of SEQ ID NO: 368; a light chain variable region CDR2 of SEQ ID NO: 369; and a light chain variable region CDR3 of SEQ
ID NO:
370. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
371; a heavy chain variable region CDR2 of SEQ ID NO: 372; a heavy chain variable region CDR3 of SEQ ID NO: 373; a light chain variable region CDR1 of SEQ ID NO: 374;
a light chain variable region CDR2 of SEQ ID NO: 375; and a light chain variable region CDR3 of SEQ ID NO: 376. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 377; a heavy chain variable region CDR2 of SEQ ID NO: 378; a heavy chain variable region CDR3 of SEQ ID NO: 379; a light chain variable region CDR1 of SEQ ID NO: 380; a light chain variable region CDR2 of SEQ ID NO: 381; and a light chain variable region CDR3 of SEQ ID NO: 382. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO: 383; a heavy chain variable region CDR2 of SEQ ID NO: 384; a heavy chain variable region CDR3 of SEQ ID NO: 385; a light chain variable region CDR1 of SEQ ID NO: 386; a light chain variable region CDR2 of SEQ ID
NO: 387; and a light chain variable region CDR3 of SEQ ID NO: 388. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P
comprising a heavy chain variable region CDR1 of SEQ ID NO: 389; a heavy chain variable region CDR2 of SEQ ID NO: 390; a heavy chain variable region CDR3 of SEQ
ID NO: 391; a light chain variable region CDR1 of SEQ ID NO: 392; a light chain variable region CDR2 of SEQ ID NO: 393; and a light chain variable region CDR3 of SEQ
ID NO:
394. In another specific embodiment, the invention includes an antibody that specifically binds to Factor P comprising a heavy chain variable region CDR1 of SEQ ID NO:
395; a heavy chain variable region CDR2 of SEQ ID NO: 396; a heavy chain variable region CDR3 of SEQ ID NO: 397; a light chain variable region CDR1 of SEQ ID NO: 398;
a light chain variable region CDR2 of SEQ ID NO: 399; and a light chain variable region CDR3 of SEQ ID NO: 400.
In certain embodiments, the invention includes antibodies or antigen binding fragments that specifically binds to Factor P as described in Table 1. In a preferred embodiment, the antibody, or antigen binding fragment, that binds Factor P is Fab NV5962, NV5963, NV5964, NV5965, NV5966, NV5967, NV5804, NV5805, NV5806, NV5807, NV5808, NV5809, NV5962-S, NV5962-Q, NV5962-G, NV5962-T, NV5962-531A, NV5965-T, NV5965-Q, or NV5965-S.
As used herein, a human antibody comprises heavy or light chain variable regions or full length heavy or light chains that are "the product of" or "derived from" a particular germline sequence if the variable regions or full length chains of the antibody are obtained from a system that uses human germline immunoglobulin genes. Such systems include immunizing a transgenic mouse carrying human immunoglobulin genes with the antigen of interest or screening a human immunoglobulin gene library displayed on phage with the antigen of interest. A human antibody that is "the product of" or "derived from" a human germline immunoglobulin sequence can be identified as such by comparing the amino acid sequence of the human antibody to the amino acid sequences of human germline immunoglobulins and selecting the human germline immunoglobulin sequence that is closest in sequence (i.e., greatest % identity) to the sequence of the human antibody. A human antibody that is "the product of" or "derived from" a particular human germline immunoglobulin sequence may contain amino acid differences as compared to the germline sequence, due to, for example, naturally occurring somatic mutations or intentional introduction of site-directed mutations. However, in the VH or VL
framework regions, a selected human antibody typically is at least 90%
identical in amino acids sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and contains amino acid residues that identify the human antibody as being human when compared to the germline immunoglobulin amino acid sequences of other species (e.g., murine germline sequences). In certain cases, a human antibody may be at least 60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, a recombinant human antibody will display no more than 10 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene in the VH or VL framework regions. In certain cases, the human antibody may display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene. Examples of human germline immunoglobulin genes include, but are not limited to the variable domain germline fragments described below, as well as DP47 and DPK9.
Homologous antibodies In yet another embodiment, the present invention provides an antibody, or an antigen binding fragment thereof, comprising amino acid sequences that are homologous to the sequences described in Table 1, and the antibody binds to a Factor P
protein (e.g., human and/or cynomolgus Factor P), and retains the desired functional properties of those antibodies described in Table 1.
For example, the invention provides an isolated antibody, or a functional antigen binding fragment thereof, comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80%, at least 90%, or at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 7,21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 and 273; the light chain variable domain comprises an amino acid sequence that is at least 80%, at least 90%, or at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, and 274; and the antibody specifically binds to Factor P (e.g., human and/or cynomolgus Factor P).
In other embodiments, the VH and/or VL amino acid sequences may be 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth in Table 1. In other embodiments, the VH and/or VL amino acid sequences may be identical except for an amino acid substitution in no more than 1,2,3,4 or 5 amino acid positions. An antibody having VH and VL regions having high (i. e., 80% or greater) identity to the VH and VL regions of those described in Table 1 can be obtained by mutagenesis (e.g., site-directed or PCR-mediated mutagenesis) of nucleic acid molecules encoding SEQ ID NOs: 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, 175, 189, 203, 217, 231, 245, 259 or 273 and SEQ ID NOs: 8,22, 36, 50, 64, 78, 92, 106, 120, 134, 148, 162, 176, 190, 204, 218, 232, 246, 260, or 274, respectively, followed by testing of the encoded altered antibody for retained function using the functional assays described herein.
In other embodiments, the full length heavy chain and/or full length light chain amino acid sequences may be 50% 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99%
identical to the sequences set forth in Table 1. An antibody having a full length heavy chain and full length light chain having high (i.e., 80% or greater) identity to the full length heavy chains of any of SEQ ID NOs : 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219, 233, 247, 261 or 275, and full length light chains of any of SEQ ID
NOs 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262, or 276, can be obtained by mutagenesis (e.g., site-directed or PCR-mediated mutagenesis) of nucleic acid molecules encoding such polypeptides, followed by testing of the encoded altered antibody for retained function using the functional assays described herein.
In other embodiments, the full length heavy chain and/or full length light chain nucleotide sequences may be 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99%
identical to the sequences set forth in Table 1.
In other embodiments, the variable regions of heavy chain and/or the variable regions of light chain nucleotide sequences may be 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth in Table 1.
As used herein, the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity equals number of identical positions/total number of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

Additionally or alternatively, the protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify related sequences. For example, such searches can be performed using the BLAST program (version 2.0) of Altschul, etal., 1990 J.Mol. Biol.
215:403-10.
Antibodies with Conservative Modifications In certain embodiments, an antibody of the invention has a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein one or more of these CDR
sequences have specified amino acid sequences based on the antibodies described herein or conservative modifications thereof, and wherein the antibodies retain the desired functional properties of the Factor P-binding antibodies of the invention.
Accordingly, the invention provides an isolated antibody, or a antigen binding fragment thereof, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, and 267, and conservative modifications thereof; the heavy chain variable region CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, and 268, and conservative modifications thereof; the heavy chain variable region CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 3, 17, 31, 45, 59, 73, 87, 101, 115, 129, 143, 157, 171, 185, 199, 213, 227, 241, 255, and 269, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 4, 18, 32, 46, 60, 74, 88, 102, 116, 130, 144, 158, 172, 186, 200, 214, 228, 242, 256, and 270, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 5, 19, 33, 47, 61, 75, 89, 103, 117, 131, 145, 159, 173, 187, 201, 215, 229, 243, 257, and 271, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 6,20, 34, 48, 62, 76, 90, 104, 118, 132, 146, 160, 174, 188, 202, 216, 230, 244, 258, and 272, and conservative modifications thereof; and the antibody or antigen binding fragment thereof specifically binds to Factor P.

In other embodiments, the antibody of the invention is optimized for expression in a mammalian cell has a full length heavy chain sequence and a full length light chain sequence, wherein one or more of these sequences have specified amino acid sequences based on the antibodies described herein or conservative modifications thereof, and wherein the antibodies retain the desired functional properties of the Factor P binding antibodies of the invention. Accordingly, the invention provides an isolated antibody optimized for expression in a mammalian cell consisting of a full length heavy chain and a full length light chain wherein the full length heavy chain has amino acid sequences selected from the group of SEQ ID NOs: 9, 23, 37, 51, 65, 79, 93, 107, 121, 135, 149, 163, 177, 191, 205, 219, 233, 247, 261 and 275, and conservative modifications thereof; and the full length light chain has amino acid sequences selected from the group of SEQ ID NOs: 10, 24, 38, 52, 66, 80, 94, 108, 122, 136, 150, 164, 178, 192, 206, 220, 234, 248, 262, and 276, and conservative modifications thereof;
and the antibody specifically binds to Factor P (e.g., human and/or cynomolgus Factor P).
Antibodies That Bind to the Same Epitope The present invention provides antibodies that bind to the same epitope as the Factor P binding antibodies described in Table 1. Additional antibodies can therefore be identified based on their ability to compete (e.g., to competitively inhibit the binding of, in a statistically significant manner) with other antibodies of the invention in Factor P
binding assays (such as those described in the Examples). The ability of a test antibody to inhibit the binding of antibodies of the present invention to a Factor P
protein demonstrates that the test antibody can compete with that antibody for binding to Factor P; such an antibody may, according to non-limiting theory, bind to the same or a related (e.g., a structurally similar or spatially proximal) epitope on the Factor P
protein as the antibody with which it competes. In a certain embodiment, the antibody that binds to the same epitope on Factor P as the antibodies of the present invention is a human monoclonal antibody. Such human monoclonal antibodies can be prepared and isolated as described herein. As used herein, an antibody "competes" for binding when the competing antibody inhibits Factor P binding of an antibody or antigen binding fragment of the invention by more than 50%, in the presence of an equimolar concentration of competing antibody.
In other embodiments the antibodies or antigen binding fragments of the invention bind the Thrombospondin type 5 repeat (TSR 5) domain of Factor P
(SEQ ID
NO: 406). In other embodiments the antibodies or antigen binding fragments of the

Claims (15)

  1. [Claim 1] An advertisement providing apparatus for receiving and providing ad-vertisements in a mobile terminal, comprising:
    an audio processor for receiving and recording an advertising audio signal, and for converting the recorded advertising audio signal into audio data;
    a transceiver for transmitting the audio data and targeting purpose data to an advertising server, and for receiving advertising information cor-responding to the audio data and the targeting purpose data from the advertising server;
    an output unit for outputting the received advertising information; and a controller for controlling the audio processor to record the advertising audio signal, and for controlling the transceiver to transmit the audio data and the targeting purpose data to the advertising server.
  2. [Claim 2] The advertisement providing apparatus of claim 1, wherein the targeting purpose data comprises at least one of terminal information, user information and location information.
  3. [Claim 3] The advertisement providing apparatus of claim 1, wherein the ad-vertising audio signal is for an advertisement, which is output from an advertising medium corresponding to any one of a Television (TV), a Personal Computer (PC) and a radio.
  4. [Claim 4] The advertisement providing apparatus of claim 1, further comprising a user input unit for receiving an input from a user;
    wherein the controller controls the audio processor to receive and record the advertising audio signal depending on whether the input from the user is a predetermined input to the user input unit.
  5. [Claim 5] The advertisement providing apparatus of claim 4, wherein the user input unit comprises a motion recognizer for recognizing a motion performed by the user on the advertisement providing apparatus, and the predetermined input is a motion of shaking the mobile terminal.
  6. [Claim 6] The advertisement providing apparatus of claim 1, wherein the ad-vertising information comprises at least one of a video, a photo, text, a web site, Uniform Resource Locator (URL) information and ap-plication information.
  7. [Claim 7] A method for providing advertisements in an advertisement providing apparatus, the method comprising the steps of:
    receiving and recording an advertising audio signal, converting the recorded advertising audio signal into audio data, and storing the audio data, at the advertisement providing apparatus;
    transmitting the audio data and targeting purpose data from the adver-tisement providing apparatus to an advertising server, and receiving ad-vertising information corresponding to the audio data and the targeting purpose data from the advertising server at the advertisement providing apparatus; and outputting the advertising information from the advertisement providing apparatus.
  8. [Claim 8] The method of claim 7, further comprising:
    receiving an input from a user at the advertisement providing apparatus; and receiving and recording the advertising audio signal at the adver-tisement providing apparatus depending on whether the input from the user is a predetermined input.
  9. [Claim 9] The method of claim 8, wherein receiving the input from the user comprises:
    receiving a motion performed by the user on the advertisement providing apparatus, wherein a predetermined motion is the prede-termined input.
  10. [Claim 10] The method of claim 9, wherein recognizing the predetermined motion comprises:
    determining whether the motion performed by the user, while the ad-vertisement providing apparatus is displaying a standby screen; and determining whether the motion performed by the user is the prede-termined motion.
  11. [Claim 11] An advertising server for providing advertisements to an advertisement providing apparatus, comprising:
    a transceiver for receiving audio data and targeting purpose data from the advertisement providing apparatus, for receiving targeting in-formation corresponding to the targeting purpose data, and for transmitting advertising information corresponding to the audio data and the targeting purpose data to the advertisement providing apparatus; and an advertising information provider for searching for the advertising in-formation corresponding to the audio data and the targeting information from among a plurality of advertising information stored in advance in an advertisement Database (DB).
  12. [Claim 12] The advertising server of claim 11, further comprising an index in-formation extractor for extracting index information corresponding to the received audio data;
    wherein the advertising information provider searches the adver-tisement DB for the advertising information corresponding to the index information and the targeting information from among the plurality of advertising information stored in advance.
  13. [Claim 13] The advertising server of claim 11, wherein the transceiver receives index information corresponding to the audio data from an audio server; and wherein the advertising information provider searches the adver-tisement DB for the advertising information corresponding to the index information and the targeting information from among the plurality of advertising information stored in advance.
  14. [Claim 14] A method for providing advertisements to an advertisement providing apparatus in an advertising server, the method comprising the steps of:
    receiving audio data and targeting purpose data from the advertisement providing apparatus;
    receiving relevant advertising information from among a plurality of advertising information stored in advance in an advertisement Database (DB), using the received audio data and the targeting purpose data; and transmitting the received advertising information to the advertisement providing apparatus.
  15. [Claim 15] The method of claim 14, wherein the targeting purpose data comprises at least one of terminal information, user information and location in-formation.
CA2859498A 2011-12-14 2012-12-14 Advertisement providing apparatus and method for providing advertisements Abandoned CA2859498A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2011-0134909 2011-12-14
KR20110134909 2011-12-14
KR1020120075695A KR20130069322A (en) 2011-12-14 2012-07-11 Apparatus and method for providing advertisement by interacting with motion
KR10-2012-0075695 2012-07-11
PCT/KR2012/010918 WO2013089487A1 (en) 2011-12-14 2012-12-14 Advertisement providing apparatus and method for providing advertisements

Publications (1)

Publication Number Publication Date
CA2859498A1 true CA2859498A1 (en) 2013-06-20

Family

ID=48864729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859498A Abandoned CA2859498A1 (en) 2011-12-14 2012-12-14 Advertisement providing apparatus and method for providing advertisements

Country Status (9)

Country Link
JP (1) JP2015507784A (en)
KR (2) KR20130069322A (en)
CN (1) CN103988569A (en)
AU (1) AU2012353108A1 (en)
BR (1) BR112014014310A2 (en)
CA (1) CA2859498A1 (en)
IN (1) IN2014CN04281A (en)
RU (1) RU2014128539A (en)
SG (1) SG11201402091PA (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101472427B1 (en) * 2013-08-23 2014-12-15 투브플러스 주식회사 Method, system and computer-readable recording medium for obtaining information on content usage by user
KR102383811B1 (en) 2019-10-23 2022-04-18 장운석 Method for posting advertisement through communication between user and broadcaster in video streaming service and method for responding to web and mobile UI

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080049704A1 (en) * 2006-08-25 2008-02-28 Skyclix, Inc. Phone-based broadcast audio identification
KR20090000164A (en) * 2007-01-22 2009-01-07 삼성전자주식회사 Method and apparatus for providing advertisement in mobile terminal, and system thereof
US9174123B2 (en) * 2009-11-09 2015-11-03 Invensense, Inc. Handheld computer systems and techniques for character and command recognition related to human movements
US8694533B2 (en) * 2010-05-19 2014-04-08 Google Inc. Presenting mobile content based on programming context

Also Published As

Publication number Publication date
KR20130069479A (en) 2013-06-26
RU2014128539A (en) 2016-02-10
JP2015507784A (en) 2015-03-12
KR20130069322A (en) 2013-06-26
AU2012353108A1 (en) 2014-05-22
CN103988569A (en) 2014-08-13
IN2014CN04281A (en) 2015-07-31
SG11201402091PA (en) 2014-06-27
BR112014014310A2 (en) 2017-06-13
AU2012353108A2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
Rossotti et al. Immunogenicity and humanization of single‐domain antibodies
Dondelinger et al. Understanding the significance and implications of antibody numbering and antigen-binding surface/residue definition
JP5791496B2 (en) Superhumanization of antibodies by blasting of putative mature CDRs and generation and screening of cohort libraries
US8748356B2 (en) Methods for use in human-adapting monoclonal antibodies
Wu et al. Fundamental characteristics of the immunoglobulin VH repertoire of chickens in comparison with those of humans, mice, and camelids
US20180016351A1 (en) Antibodies comprising sequences from camelidae to highly conserved targets
CN110612308B (en) Method for preparing pH dependent antibodies
CA2491864A1 (en) Super humanized antibodies
JP2020535799A5 (en)
EP2686349B1 (en) Antibody screening methods
EP4036116A1 (en) Anti-vhh domain antibodies and use thereof
NZ601583A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
JP2020524510A5 (en)
US20230279115A1 (en) Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
McConnell et al. High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation
US20170088611A1 (en) Single-chain multivalent binding protein compositions and methods
Tillotson et al. Engineering an anti-transferrin receptor ScFv for pH-sensitive binding leads to increased intracellular accumulation
US20220204610A1 (en) Protein binders for irhom2
CN114761426A (en) Method for producing a biotherapeutic drug with increased stability by sequence optimization
US20240076403A1 (en) Her2 antibody and application thereof
JP2010508290A (en) Methods for use with human-compatible monoclonal antibodies
Groves et al. Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity
CA2859498A1 (en) Advertisement providing apparatus and method for providing advertisements
CN113677701A (en) Method for generating affinity binding multispecific antibodies
JP2023109923A (en) Humanized antibodies against globo h and uses thereof in cancer treatments

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20181214